US 12,233,116 B2
IL-15-based fusions to IL-12 and IL-18
Warren D. Marcus, Miramar, FL (US); Robert Newman, Miramar, FL (US); Bai Liu, Cooper City, FL (US); Lijing You, Miramar, FL (US); Lin Kong, Miramar, FL (US); Peter Rhode, Miami, FL (US); and Hing C. Wong, Weston, FL (US)
Assigned to Altor Bioscience, LLC., Culver City, CA (US)
Filed by Altor Bioscience LLC, Culver City, CA (US)
Filed on Sep. 25, 2024, as Appl. No. 18/896,286.
Application 18/896,286 is a division of application No. 18/611,464, filed on Mar. 20, 2024.
Application 18/611,464 is a continuation of application No. 18/526,598, filed on Dec. 1, 2023, granted, now 11,975,059, issued on May 7, 2024.
Application 18/526,598 is a continuation of application No. 18/168,428, filed on Feb. 13, 2023, granted, now 11,872,272, issued on Jan. 16, 2024.
Application 18/168,428 is a continuation of application No. 17/820,980, filed on Aug. 19, 2022, granted, now 11,612,645, issued on Mar. 28, 2023.
Application 17/820,980 is a continuation of application No. 17/486,683, filed on Sep. 27, 2021, granted, now 11,571,470, issued on Feb. 7, 2023.
Application 17/486,683 is a continuation of application No. 15/913,837, filed on Mar. 6, 2018, granted, now 11,129,883, issued on Sep. 28, 2021.
Claims priority of provisional application 62/467,623, filed on Mar. 6, 2017.
Prior Publication US 2025/0018020 A1, Jan. 16, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C12N 15/62 (2006.01)
CPC A61K 39/00114 (2018.08) [A61K 39/4613 (2023.05); A61K 39/46444 (2023.05); A61K 47/6811 (2017.08); A61P 35/00 (2018.01); C07K 14/54 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/715 (2013.01); C07K 16/283 (2013.01); C12N 15/62 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/30 (2013.01)] 6 Claims
 
1. A pharmaceutical composition comprising natural killer (NK) cells and
an isolated soluble fusion protein complex comprising a first soluble protein comprising an interleukin-15 (IL-15) polypeptide domain and an IL-18 polypeptide domain, and a second soluble protein comprising a soluble IL-15 receptor alpha sushi (IL-15RαSu) polypeptide domain and an IL-12 polypeptide domain, wherein the IL-15 polypeptide domain binds to the IL-15RαSu polypeptide domain to form the soluble fusion protein complex,
wherein the pharmaceutical composition is formulated for administration.